A Single-Blind, Placebo-Control, Randomized Phase 2 Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas
Latest Information Update: 04 Nov 2024
At a glance
- Drugs CBL-514 (Primary)
- Indications Adiposis dolorosa
- Focus Adverse reactions; Therapeutic Use
- Sponsors Caliway Biopharmaceuticals
- 30 Oct 2024 Planned End Date changed from 3 Sep 2025 to 1 Nov 2025.
- 30 Oct 2024 Planned primary completion date changed from 3 Sep 2025 to 1 Aug 2025.
- 30 Oct 2024 Planned initiation date changed from 18 Sep 2024 to 1 Dec 2024.